Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

PURPOSE: Lorlatinib is a third-generation ALK tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, other resistance mechanisms driving lorlati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Recondo, Gonzalo, Mezquita, Laura, Facchinetti, Francesco, Planchard, David, Gazzah, Anas, Bigot, Ludovic, Rizvi, Ahsan Z., Frias, Rosa L., Thiery, Jean-Paul, Scoazec, Jean-Yves, Sourisseau, Tony, Howarth, Karen, Deas, Olivier, Samofalova, Dariia, Galissant, Justine, Tesson, Pauline, Braye, Floriane, Naltet, Charles, Lavaud, Pernelle, Mahjoubi, Linda, Abou Lovergne, Aurélie, Vassal, Gilles, Bahleda, Rastislav, Hollebecque, Antoine, Nicotra, Claudio, Ngo-Camus, Maud, Michiels, Stefan, Lacroix, Ludovic, Richon, Catherine, Auger, Nathalie, De Baere, Thierry, Tselikas, Lambros, Solary, Eric, Angevin, Eric, Eggermont, Alexander, André, Fabrice, Massard, Christophe, Olaussen, Ken A., Soria, Jean-Charles, Besse, Benjamin, Friboulet, Luc
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942925/
https://ncbi.nlm.nih.gov/pubmed/31585938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados